SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
IGM Biosciences, Inc. (IGMS) .
Criteria proven by this page:
- VALUE (90/100, Pass) — analyst target implies upside (+37.8%).
- Analyst consensus target $1.75 (+37.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 43/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — IGMS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio28.69
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.24
Book Value / Share$0.00
Revenue / Share$0.04
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$1.75 (+37.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-25.24 |
$0.00 |
$-11.05M |
- |
| 2018 |
$-51.84 |
$0.00 |
$-22.71M |
- |
| 2019 |
$-4.73 |
$0.00 |
$-42.54M |
- |
| 2020 |
$-2.61 |
$0.00 |
$-80.33M |
- |
| 2021 |
$-4.80 |
$0.00 |
$-160.68M |
- |
| 2022 |
$-5.16 |
$1.07M |
$-214.25M |
-20041.9% |
| 2023 |
$-4.71 |
$2.13M |
$-246.42M |
-11568.8% |
| 2024 |
$-3.24 |
$2.68M |
$-195.8M |
-7308.5% |
